Interim report January – March 2023: 2023 STARTED VERY STRONGLY

FIRST QUARTER 2023 (JAN – MAR)

Net sales amounted to SEK 229.1 million (159.1), corresponding to an increase of 44 percent compared with the corresponding period in the preceding year.

License revenues roughly doubled to SEK 70.6 million (35.7) and accounted for 31 percent of net sales (22).

Operating profit amounted to SEK 53.3 million (20.0).

Net profit amounted to SEK 49.8 million (16.5), corresponding to earnings per share of SEK 0.98 (0.32).

Cash flow from operating activities amounted to SEK 60.5 million (11.1). As of March 31, 2023, cash and cash equivalents amounted to SEK 482.1 million (329.9).

Gothenburg, Sweden, May 16, 2023
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

---

Gisli Hennermark, CEO
Telephone: [phone]
E-mail: [e-mail]

Anna Ahlberg, CFO
Telephone: [phone]
E-mail: [e-mail]

About Surgical Science Sweden AB (publ)

---

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 250 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-16 07:30 CEST.

Attachments

---

230516 Q12023 ENG

© Modular Finance, source Nordic Press Releases